Colorectal cancer: cetuximab,KRAS,BRAF,PIK3CAmutations and beyond

Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice

(2010) Dimitrios H Roukos   Biomarkers in Medicine

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

(2010) Jolien Tol et al.   EUROPEAN JOURNAL OF CANCER

Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?

(2010) Dimitrios H Roukos   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Genotype–phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment

(2010) Dimitrios H Roukos et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Human genome at ten: The sequence explosion

(2010)   NATURE

Statistical inference for noisy nonlinear ecological dynamic systems

(2010) Simon N. Wood   NATURE

The human genome at ten

(2010)   NATURE

Human genome at ten: Life is complicated

(2010) Erika Check Hayden   NATURE

Big science: The cancer genome challenge

(2010) Heidi Ledford   NATURE

Multiple personal genomes await

(2010) J. Craig Venter   NATURE

Has the revolution arrived?

(2010) Francis Collins   NATURE

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Individual genomes and personalized medicine: life diversity and complexity

(2010) Christos Katsios et al.   Personalized Medicine

Systems medicine: a real approach for future personalized oncology?

(2010) Dimitrios H Roukos   PHARMACOGENOMICS

Complete genome sequencing and network modeling to overcome trastuzumab resistance

(2010) Dimitrios H Roukos   PHARMACOGENOMICS

Breast Cancer Outcomes: The Crucial Role of the Breast Surgeon in the Era of Personal Genetics and Systems Biology

(2009) Dimitrios H. Roukos   ANNALS OF SURGERY

Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice

(2009) Dimosthenis Ziogas et al.   ANNALS OF SURGICAL ONCOLOGY

Genome-Wide Association Studies and Aggressive Surgery Toward Individualized Prevention, and Improved Local Control and Overall Survival for Gastric Cancer

(2009) Dimitrios H. Roukos   ANNALS OF SURGICAL ONCOLOGY

Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance

(2009) Dimitrios H. Roukos   ANNALS OF SURGICAL ONCOLOGY

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer

(2009) Dimitrios H Roukos et al.   Expert Review of Anticancer Therapy

Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care

(2009) Dimitrios H Roukos   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

(2009) Daniel Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

When it is time to die

(2009) Philippe Bastiaens   NATURE

Molecular networks as sensors and drivers of common human diseases

(2009) Eric E. Schadt   NATURE

Complex landscapes of somatic rearrangement in human breast cancer genomes

(2009) Philip J. Stephens et al.   NATURE

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

New, but Not Improved? Incorporating Comparative-Effectiveness Information into FDA Labeling

(2009) Randall S. Stafford et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Reverse engineering the genotype–phenotype map with natural genetic variation

(2008) Matthew V. Rockman   NATURE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE